Plain-English translation of NCT06026735 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are collecting cerebrospinal fluid (the fluid around your brain and spinal cord), blood samples, and tumor tissue from people with non-small cell lung cancer that has spread to the brain. They will analyze tiny particles called exosomes in these samples to identify markers — like fingerprints — that could help doctors better predict how your cancer will progress and whether your treatment is working.
When lung cancer spreads to the brain, it becomes much harder to treat and predict outcomes. Doctors need better tools to understand which patients will respond to treatment and how to monitor their progress. This study hopes that examining these special markers in body fluids and tissue will lead to better ways to detect cancer spread and track treatment success.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would provide three types of samples: cerebrospinal fluid (collected during a spinal tap or during brain surgery), a blood draw, and tumor tissue (either from your surgical resection or from a drainage procedure). The samples would be collected as part of your planned medical care, and researchers would then study the exosomes in these samples over time to look for patterns. The study is enrolling about 30 people total.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
Taiwan